XTENT, Inc. Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a XTENT, Inc.'s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

• Details of development stage by sector and equipment type.
• Pipeline products grouped by therapy area, development stage and trial phase.
• Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
• Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
• Product updates covering estimated approval dates and estimated launch dates.
• Descriptions of novel technologies relating to pipeline products of the company.
• Patents and patent applications covered for the product.
• News updates on key events relating to the product and its development.

Reasons to buy

• A single source to fulfill competitor information relating to products in development.
• Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

• Access clinical trial information to map trial results and plan targeted marketing activities.
• Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
• Identification of potential investment opportunities.
• Build up knowledge base for potential distribution and marketing partners.
• Helps avoid patent infringement.
• Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Contents

• 1.1 List Of Tables
• 1.2 List of Figures
• 2 Company Overview
• 2.1 Key Information
• 2.2 Financial Performance
• 2.3 Industry Outlook - Cardiovascular Devices
• 3 Major Products and Services
• 3.1 Overview
• 4 Competitors
• 5 Key Employees
• 6 Locations And Subsidiaries
• 6.1 Head Office
• 7 Recent Developments
• 7.1 Financial Announcements
  • 7.1.1 Aug 06, 2008: XTENT Reports 2Q 2008 Results
  • 7.1.2 Apr 28, 2008: XTENT Declares Q1 2008 Results
  • 7.1.3 Feb 19, 2008: XTENT Declares Q4 2007 Results
  • 7.1.4 Nov 02, 2007: XTENT Declares Q3 2007 Results
  • 7.1.5 Nov 02, 2007: XTENT Reports Q3 2007 Results
  • 7.1.6 Aug 07, 2007: XTENT Declares Q2 2007 Results
  • 7.1.7 May 08, 2007: XTENT Declares Q1 2007 Results
  • 7.1.8 Feb 21, 2007: XTENT Declares Q4 2006 Results
• 7.2 Corporate Communications
  • 7.2.1 Jul 10, 2008: XTENT Executives Resign
  • 7.2.2 Jun 20, 2008: XTENT Appoints New Board Members
  • 7.2.3 Aug 13, 2007: XTENT Appoints New Board Member
  • 7.2.4 May 11, 2006: XTENT Appoints CFO
• 7.3 Product News
  • 7.3.1 Jun 23, 2008: XTENT Announces European Regulatory Update
  • 7.3.2 May 13, 2008: XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented At EuroPCR Meeting
  • 7.3.3 Dec 27, 2007: XTENT Submits CE Mark Registration To Market Custom NX Drug-Eluting Stent System In Europe
  • 7.3.4 Oct 22, 2007: XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data For Novel Drug-Eluting Stent System
  • 7.3.5 May 22, 2007: XTENT Announces Promising Six-Month Custom II Trial Data Presented At EuroPCR Meeting
  • 7.3.6 May 16, 2006: Xtent CUSTOM I Trial Shows Zero Restenosis, Favorable Late Loss Results At Eight Months
• 7.4 Clinical Trials
  • 7.4.1 May 13, 2008: XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented At EuroPCR Meeting
  • 7.4.2 Oct 22, 2007: XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data For Novel Drug-Eluting Stent System
  • 7.4.3 May 22, 2007: XTENT Announces Promising Six-Month Custom II Trial Data Presented At EuroPCR Meeting
  • 7.4.4 May 16, 2006: Xtent CUSTOM I Trial Shows Zero Restenosis, Favorable Late Loss Results At Eight Months
• 8 XTENT, Inc. Pipeline Products
• 8.1 XTENT, Inc. Product Pipeline Analysis
  • 8.1.1 XTENT, Inc. Pipeline Products By Equipment Type
  • 8.1.2 XTENT, Inc. Pipeline Products By Development Stage
  • 8.1.3 XTENT, Inc. Pipeline Products By Therapy Area
  • 8.1.4 XTENT, Inc. Pipeline Products By Clinical Trials
  • 8.1.5 XTENT, Inc. Pipeline Products By News Summary
• 8.2 Custom NX 60
  • 8.2.1 Product Description
  • 8.2.2 Product Status
  • 8.2.3 Clinical Trials
  • 8.2.4 Product Milestone
  • 8.2.5 Product Patent Details
  • 8.2.6 Product Patent Details
  • 8.2.7 Product Patent Details
  • 8.2.8 Product Patent Details
  • 8.2.9 Product Patent Details
  • 8.2.10 Product Patent Details
  • 8.2.11 Product Patent Details
• 8.3 Custom Bare Metal Stent System
  • 8.3.1 Product Description
  • 8.3.2 Product Status
  • 8.3.3 Clinical Trials
• 8.4 Custom NX 36 Drug eluting stent
  • 8.4.1 Product Description
  • 8.4.2 Product Status
  • 8.4.3 Clinical Trials
  • 8.4.4 Product Milestone
  • 8.4.5 Product Patent Details
• 8.5 Nitinol Self expanding peripheral artery stent
  • 8.5.1 Product Description
  • 8.5.2 Product Status
• 8.6 Bioabsorbable Stent System
  • 8.6.1 Product Description
  • 8.6.2 Product Status
• 8.7 Quick Deployment Handles
  • 8.7.1 Product Description
  • 8.7.2 Product Status
• 9 Appendix
• 9.1 Methodology
  • 9.1.1 Coverage
  • 9.1.2 Secondary Research
  • 9.1.3 Primary Research
  • 9.1.4 Expert Panel Validation
• 9.2 Contact Us
• 9.3 About Global Markets Direct
• 9.4 Disclaimer
• 1 List of Tables
• Table 1: XTENT, Inc.,Key Facts
• Table 2: XTENT, Inc., Key Employees,
• Table 3: XTENT, Inc. Pipeline Products by Equipment Type
• Table 4: XTENT, Inc. Pipeline Products By Development Stage
• Table 5: XTENT, Inc. Pipeline Products By Therapy Area
• Table 6: XTENT, Inc. Pipeline Products By Clinical Trials
• Table 7: XTENT, Inc. Pipeline Products By News Summaries
• 1.2 List of Figures
• Figure 1: XTENT, Inc. Pipeline Products By Development Stage
• Figure 2: XTENT, Inc. Pipeline Products By News Summary
• Figure 3: Global Markets Direct Methodology